In case you missed it at Ross’ site, here’ Uwe Reinhardt’s guide for journalists ot the health care debate. Brilliant, and rather tragic. More at his site.
PHARMA: The New Yorker, Industry Veteran and Atlas on pharma pricing and where the industry goes next.
There’s a pretty long article by Malcolm Gladwell in the New Yorker called High Prices in which he essentially places much of the blame for big pharma’s current state on the other actors in the system being too dumb to stop them. To quote his conclusions.
For sellers to behave responsibly, buyers must first behave intelligently. And if we want to create a system where millions of working and elderly Americans don’t have to struggle to pay for prescription drugs that’s also up to us. We could find it in our hearts to provide all Americans with adequate health insurance. It is only by the most spectacular feat of cynicism that our political system’s moral negligence has become the fault of the pharmaceutical industry.
There is a second book out this fall on the prescription-drug crisis, called "Overdosed America", by John Abramson, who teaches at Harvard Medical School. At one point, Abramson discusses a study that he found in a medical journal concluding that the statin Pravachol lowered the risk of stroke in patients with coronary heart disease by nineteen per cent. That sounds like a significant finding, but, as Abramson shows, it isn’t. In the six years of the study, 4.5 per cent of those taking a placebo had a stroke versus 3.7 per cent of those on Pravachol. In the real world, that means that for every thousand people you put on Pravachol you prevent one stroke–which, given how much the drug costs, comes to at least $1.2 million per stroke prevented. On top of that, the study’s participants had an average age of sixty-two and most of them were men. Stroke victims, however, are more likely to be female, and, on average, much older–and the patients older than seventy in the study who were taking Pravachol had more strokes than those who were on a placebo.
Here is a classic case of the kind of thing that bedevils the American health system–dubious findings that, without careful evaluation, have the potential to drive up costs. But whose fault is it? It’s hard to blame Pravachol’s manufacturer, Bristol-Myers Squibb. The studys principal objective was to look at Pravachol’s effectiveness in fighting heart attacks; the company was simply using that patient population to make a secondary observation about strokes. In any case, Bristol-Myers didn’t write up the results. A group of cardiologists from New Zealand and Australia did, and they hardly tried to hide Pravachol’s shortcomings in women and older people. All those data are presented in a large chart on the study’s third page. What’s wrong is the context in which the study’s findings are presented. The abstract at the beginning ought to have been rewritten. The conclusion needs a much clearer explanation of how the findings add to our understanding of stroke prevention. There is no accompanying commentary that points out the extreme cost-ineffectiveness of Pravachol as a stroke medication–and all those are faults of the medical journal’s editorial staff. In the end, the fight to keep drug spending under control is principally a matter of information, of proper communication among everyone who prescribes and pays for and ultimately uses drugs about what works and what doesn’t, and what makes economic sense and what doesn’t–and medical journals play a critical role in this process. As Abramson writes:
When I finished analyzing the article and understood that the title didn’t tell the whole story, that the findings were not statistically significant, and that Pravachol appeared to cause more strokes in the population at greater risk, it felt like a violation of the trust that doctors (including me) place in the research published in respected medical journals.
The journal in which the Pravachol article appeared, incidentally, was The New England Journal of Medicine. And its editor at the time the paper was accepted for publication? Dr. Marcia Angell. Physician, heal thyself.
Now Gladwell may have caught Angell out here, albeit at a remote distance, and I haven’t always been too kind to her on the pages of THCB. But there is a battle going on for the soul of big pharma with one side urging the best pharmaceutical be used at the best time, creating the real information behind that, and accepting that a generic may be more cost-effective than a brand. On the other side is the decision to beef up the sales force, fudge the details of the science at the marketing margins, and financially smother physicians and politicians. The disinterested observer would not incorrect in noticing that whenever big pharma has had the choice to go down the former road, they’ve almost always taken the latter. The Industry Veteran, it may not surprise you to know, has limited time for Caldwell’s analysis:
It’s ostensibly a review of Marcia Angell’s book but it’s actually a New Yorkerized version of the PhRMA boilerplate. His major argument rests on his assertion that volume of drug usage (due to an aging population and greater awareness) is the principal driver of increasing pharmaceutical cost, not unit pricing. The reason this Gladwell fellow is a shill is that he completely ignores the malevolent DTC advertising by the drug companies and their role as the principal provider of continuing therapeutic education for physicians. It is Big Pharma’s propaganda that drives patients and physicians toward the ever more costly, branded me-too’s and away from the vastly cheaper generics.
Gladwell then takes a flying leap into the arms of the Bush ideologues when he defends the me-too’s, claiming that their proliferation drives down prices. Perhaps that obtains in an ideal world or in some Friedmanite wet dream, but in reality the oligopolistic behavior of product competitors in a therapeutic drug category almost never restrains prices.
Next, Gladwell gets all dreamy eyed and rhapsodic over PBMs and how their role in the Bush Medicare scheme, starting in 2006, can restrain prices by pushing people to generics and less costly brands. Were it only so. In his eagerness to exculpate Big Pharma, he completely ignores the fact that they try to subvert the very algorithms and step formulary approaches he suggests through mutli-therapy bundling, volume incentives and rebates that require the exclusion of competitors.
Gladwell then finishes with a minor anecdote, claiming that the sleight-of-hand conclusions that appeared in a journal article on Pravachol were not the fault of Bristol-Myers Squibb. Instead he blames the investigators and the journal’s editor: Marcia Angell. Someone’s got to take this guy out back and beat the crap out of him.
In general I agree with The Veteran although probably not about the crap beaten out of him part. There’s almost no evidence to show that multiple "me-too" drugs in a class lower the overall costs. Lipitor is much costlier than Crestor, and bang for the buck wise, much much much costlier than Mevacor which is now generic. So which one is the most prescribed drug? I don’t have to tell you. PBMs have been co-opted by pharmas and made far too much of their money by playing favorites among brand-managers, with their rebates from manufacturers exceeding their income from medical management. Finally, while the NEJM article might have been in dispute, that’s not how doctors really get their news. I’m sure that the BMS detail babes gave a fair and balanced discussion of what was in effect quasi off-label use for Pravachol in the few minutes they got in front of a doctor, but let’s face it, that session rather than academic probing of journal articles is where doctors get their information, and what drives the prescribing decisions.
But, and I’m sorry to harken back to this, I think that there is both a middle ground here, and the inevitability that pharma must change in and of itself, whether the health care purcasing market demands it or not. Atlas, who is on the other end of the political spectrum from The Veteran comes to much the same conclusion in this article in which he bashes Angell and all those socialists, but more importantly notes that the party can’t go on forever.
Marcia Angell and her Harvard/Martha’s Vineyard/New England Journal of Medicine fellow travelers live in a worker’s paradise that is in permanent denial of the evident failures of socialism and communism. For years, they have been pushing for a national healthcare system to no avail, because, thankfully, most Americans are not fooled by their well meaning naivete into believing that there is a free lunch. We all wish we could get something for nothing but we can’t so we work. This sort of commonsense eludes the overeducated hothouse flowers who promulgate such wishful thinking on the unsuspecting electorate.
All that having been said, is there room for improvement in the pharmaceutical business? You bet. And it will come soon. The next decade will be then Gotterdamerung for the deities of big pharma. It will not kill them (hopefully) so it will make them stronger. Bye bye DTC. Bye bye salesforce. Bye bye CME. Bye bye sampling. Hello efficient, effective marketing like real businesses do–direct marketing, business to business advertising,and al the good old fashioned stuff that has been replaced by six figure deliverymen bearing so much free product that the typical group practice sample cabinet is better stocked than most Wal Mart pharmacies.
The recent Rx marketing orgy isn’t sustainable and nobody knows that better than its perpetrators. Somebody has to blow the whistle and fill the penalty box, and it will be surely be Kerry if he’s wearing the striped shirt. But even a Bush II administration will be giving big pharma a buzz cut, although they may use a scissors instead of a razor.
So it’s a fair bet that many of the bad excesses will be driven out by a combination of regulation and market forces. I agree here too, which yet again puts me in the wishy-washy political middle ground! And at that point the system (hopefully prodded by some sensible bodies acting something like the UK’s NICE) will begin to determine what drugs really work at what cost overall, and those with the desire to play the "full cost of care" argument within the pharmas will take over from those who’ve been running the "marketing orgy".
HEALTH PLANS: Did Eliot Spitzer short the health plan index?
It seems like only yesterday I was posting about how much money health plans were making, and that only I and Don Johnson thought they were overvalued. Well not for any reason that I or Don gave, but all the big ones are down 6-8% on news that Eliot Spitzer has included Cigna in his investigation of the insurance business.
By the way, yes the headline is (meant to be) a joke.
POLITICS: “Movable” voters in the swing states care about health care
A fascinating 2 pager from the kaiser Family Foundation looks at opinion polls in three swing states, Iowa, Ohio and Minesotta. There are some really amazing things in here:
A poll conducted October 8-11, 2004 by Market Shares Corp. for the Chicago Tribune among likely voters in key Midwest swing states found that health care ranked first as an issue of concern to voters in Iowa and Wisconsin, and ranked second behind job losses and unemployment in Ohio. Three weeks earlier, a series of polls conducted by Mason-Dixon Polling and Research for Knight Ridder and MSNBC found that health care ranked lower as a voting issue in these same states, behind terrorism and the economy (and in some cases behind other issues such as Iraq and jobs as well).
What was the difference? Well one difference was the 3 weeks between the two polls, but the main diffference was that one question asked “Which one of these are you most concerned about?” while the other asked “Which one of the following issues will be most important in determining your vote for President”. The latter found terrorism and Iraq most important. You’d think that should help Bush as he apparently does better in the polls in those two issues, and those are the ones people say will affect their vote (in an apparent rush of altruism — Bush is better for the country but I’ll be worse off!?”).
But by now pretty much everyone knows where they stand on those issues. The people who don’t are the “undecideds” or the “movable voters” who will of course be a big part of deciding who wins. ABC did a nationl poll of undecideds:
Turning to swing voters rather than swing states, another recent finding that sheds some light on the role that health care may play as a voting issue comes from a national poll conducted October 7-10 by ABC News. This poll defined “moveable voters” as those likely voters who either said they were undecided in their vote choice, or there was a chance they might change their mind (15% of all likely voters in the poll). When given a list and asked which would be the single most important issue in their vote for president, 24% of movable voters chose health care, compared with 9% of voters who had made up their minds, indicating that health care might play a larger role in vote choice among swing voters than in the population in general.
Now you have to do some methodological fudging, but assuming that the undecideds in the swing states are like the undecideds nationally, they will be voting about health care because they can’t get to an answer about the other stuff.
For the life of me, especilly given the unpopularity of the Medicare bill, I cannot understand why Kerry isn’t running wall-to-wall ads about health care in all the swing states.
BLOGS: A Kosalanche hits THCB
Ahh, the power of the superblogs. A tiny reference to THCB in a posting by MeteorBlades, a regular on the Dem friendly Daily Kos blog made yesterday my most popular day ever at THCB. And the article by MeteorBlades on healthcare rationing was a very good one–similar to this excellent article by Humphrey Taylor called “The health care debate we are not having”. Thanks for the compliment, MB, and welcome to those of you who came by.
You might also note some excellent stuff in the 240 comments that the original article got! But be warned some of those guys have got all day to write that stuff….and it takes nearly as long to read it all!
POLICY: Medicare and admin costs, again.
In today’s post I risk upsetting The Veteran even more, by featuring a new comment from Joe Crea, a doc who’s run off to academia and so doesn’t need to care what anyone thinks of him! Joe is peeved at my comment in Friday’s post that:
Hence I’m told again and again that government healthcare would be inefficient (as I heard from a Democrat I met tonight), despite the fact that Medicare’s admin costs are 3% while private insurance’s costs are 8-15%. You’d think that the onus would be on the defenders of the staus quo to show why a change would be worse.
I later went on to say:
But it is a long way from being a government dictated-system like that of Canada or the UK. Given the record of American private health care, that may be a bad thing…
Joe thinks that there is a flaw in my logic:
One of my pet peeves is the presenting of “the fact that Medicare’s admin costs are 3%” without appropriate qualification or explanation. I have attached such a succinct qualification here, courtesy of Healthleaders.
“Medicare overhead has the appearance of a gold standard: 2.1 percent overhead compared to a commercial average of 13 percent and a “best practices” company commercial average in the range of 5-8 percent. Medicare clearly has economies of scale, but its overhead figure is a bit misleading. The average per-member-per-month premium for commercial HMOs in now in the $200-$250 range, while the typical PMPM for Medicare is in the $600 range. If the Medicare PMPM were $200 rather than $600, then it would have an administrative overhead of 6.3 percent rather than 2.1 percent-still very good, but not out of the range of the very lowest-cost private insurers.
“For that relatively low overhead, Medicare offers only a single product (little choice except in urban areas where Medicare+Choice is available), provides limited medical management (and that seemingly by lawsuit), conducts provider contracting by fiat (negotiations take place in Congress), and has almost no marketing costs (no competitors).”
The other two things that are not mentioned are the hiding of the debt service to other areas of the government, and the shifting of administrative costs to providers by way of mandates and voluminous paperwork.
Now the article Joe references does take a look at the “best practice” plans with the lowest medical loss ratios. They tend to be big monopoly Blues in rural states, or staff/group model HMOs which practice shoulder to shoulder restraint (or push medical management doen to the physician level). But with the exception of Kaiser they are not the core private health insurers that dominate the national market. Those guys not only have very high admin costs (or in the jargon “low medical loss ratios”) but are making them higher. Following United Health Group raising its profit forecasts CBS Marketwatch reports that Health insurers (are) getting bigger cut of medical dollars:
From 2000 to 2003, medical loss ratios for the 17 companies dropped from an average of 84.8 percent four years ago to 81.5 percent last year. So while medical expenses have increased, the proportion of dollars devoted to them has dropped.
So for the bigger players getting bigger, more money is sticking with them, so adminstrative costs are going up not down. And, duh, that’s the way the system is designed. Everyone at Anthem, Pacificare, Wellpoint, Aetna, etc, etc is incented to try to reduce their medical loss ratio.
Now that might not be such a bad thing if they were truly managing care, auditing for quality, and increasing the amount they’re spending on administrative functions in order to reduce the amount being spent on medical care. But if you think that’s what they’ve been doing for the last 5 years, you really haven’t been paying attention. I talked to a VP of HR at a very, very big telecoms company last week, and she disputed my notion that the health plan’s clients (like her) haven’t been holding their feet to the fire. She claimed that they’d done huge amounts to try reduce their costs. I said, “Tell me another industry that supplies you from which you’ve accepted 15% annual increases in costs for no perceived additional benefits for the last 5 years in a row?” The HR VP went very quiet.
Now maybe Joe is right and we should be calculating Medicare’s admin charge on its higher cost per case. But even at 6% it looks pretty good compared to all but monopoly Blues plans. In other words Medicare and those plans all share a bunch of characteristics leading to their low overhead (from the same Healthleaders article):
- Economies of scale in a single state (Blue Cross Blue Shield of Alabama and Blue Cross Blue Shield of Tennessee)
- A narrow geographic focus (Capital Group, Fallon, Kaiser)
- Off-loading medical management expenses to capitated medical groups or IPAs (Kaiser, Fallon, Capital Group)
- Market leader position (Fallon, Capital Group, Blues of Alabama and Blues of Tennessee), lowering marketing costs
- Comparatively narrow product offering (Fallon, Capital Group, Kaiser, BCBS of Alabama)
I’d actually dispute Joe’s point about Medicare off-loading admin work to providers. Given the lack of UR in the Medicare system I think it off-loads less admin onto providers than private insurers–certainly it doesn’t create more. And because it’s so big and only needs things done one way, it’s a lot less work for providers than dealing with 5-10 plans of the same cumulative size who all want things done just their way (the thing that HIPAA simplification was supposed to do). But even if he’s right, Medicare’s adminstrative cost is as low as it is because of all the things he finds so terrible such as being able to set its own provider rates, only offering a limited “product” line up, limited medical management, etc. The problem is that private health plans are “charging” through the nose to deliver all those things and yet it just costs more and more with no apparent gains. And those “charges” are increasing (or the MLRs are going down).
So let me ask one more time. Why is the onus on the government program to prove that it is more administratively efficient than private plans when it already is, and they are getting less efficient?
Coda: I don’t want you to think that I’m a huge fan of the way Medicare works. I think it needs drastic changes, including upping its oversight of the system and changing the way it pays providers to a performance-based reimbursement system. And I said as much in the very first post of THCB. But given its huge clout and the government’s ability to change the law, I think a reformed Medicare could do that in a way that will improve the care delivered at a lower cost, bloody battle though that’ll be. The private plans’ record of the the last 5 years shows no sign that they could.
PHARMA: Doctor says drug firms ghost write medical articles, with UPDATE from The Industry Veteran
Given the controversy over Vioxx, big Pharma’s PR and The Lancet‘s fight with Crestor last year, this headline from a British government enquiry is pretty explosive stuff. Doctor says drug firms ghost write medical articles. And the articles that are being discussed are ones that are peer-reviewed and in major journals including The Lancet:
Professor David Healy, of the University of Wales, told the House of Commons health select committee on Thursday that as many as half the articles published in journals such as the British Medical Journal and The Lancet were written by members of the industry who had a vested interest in selling the drugs involved. Respected clinicians were then paid to have their names put at the top of the articles, he said, even though they had not seen the raw data on which they were based.
Whether there’s much truth in these allegations remains to be seen, but given what’s gone on in the scandal plagued relationship between doctors and pharma….well let me give you an analogy. I’m a San Francisco Giants fan, and I hope that Barry Bonds wasn’t using steroids, but when his personal trainer says he was I’m starting to believe that smoke and fire connection.
Of course, it might only be those British and Austrian academics and European drug companies who behave like that!
UPDATE: The Industry Veteran, who has more than mild opinions about the behavior of pharma companies and that of the doctors they work closely with, suprisingly enough has something to say about this story and THCB’s mealy-mouthed moderation:
Your hints of qualification and skepticism in “Doctor says drug firms ghost write medical articles” require admonition. After the last few years, how can anyone seriously entertain doubts that a substantial portion of research articles authored by key opinion leaders (KOLs in industry shorthand) are actually written by the pharmaceutical companies? We’re not talking here about cases where these superwhores conduct a study that the sponsoring company then writes up; what Professor Healy and others describe are the numerous instances where the KOLs never even get involved in the study. The sponsors and their investigators who lack any national recognition frequently conduct studies and then pay a superwhore for attaching his name as the lead author. The sponsor can conduct the study far more cheaply because they needn’t pay for the KOL’s retinue of postdocs, administrators, data coordinators and the rest. The KOL gets compensation for the use of his name and a publication that embellishes his expertise in a cutting edge area, thereby raising his speaking fees and consulting credentials. The practice has actually created an entire, parasitic industry of “medical ommunications companies” that write journal articles and create PowerPoint slides that KOLs present at conventions. I find it amusing that pharmaceutical marketers will express high indignation that they have paid a KOL hundreds of thousands of dollars for articles, speaking fees, train-the-trainer sessions and so forth, only to find that after a year or so, the slime bucket trades upon this burnished expertise to collect higher fees from another manufacturer with a competing, new product. Imagine that, refusing to do business on a bought-and-paid-for basis! Well, I guess that is the market at work, that holy of holies according to your physician contributors and the Bush ideologues.
POLICY: Why dishonesty rules in our health care “debate”
Bush has certainly been attacking Kerry on his health care program. Jonathan Cohn is an editor at the New Republic who specializes in health care and is currently a Kaiser Family Foundation media fellow. For those of you who don’t track the political leanings of the weeklies, the New Republic is the Clintonian Democratic magazine, way to the right of the leftish The Nation, while far to the left of the conservative National Review. Cohn’s latest piece has been reproduced on CBS web-site which may (or more likely may not) hint at whom CBS’ parent Viacom wants to win the election.
In any event he does a much better job than Kerry has done himself on crying bullshit at Bush’s attempt to call the Kerry plan a government takeover of health care. In the article called A Guide To Bushspeak On Healthcare Cohn says:
The Clinton health care plan really was a government-run health plan (albeit one that was hardly the menace its critics warned it would be). That’s simply not the case with Kerry’s health plan, for reasons that I (among many others) have already written about. Today, in fact, a group of 68 health care policy experts led by Mark Peterson at the University of California at Los Angeles, released a petition calling upon the Bush campaign to end its gross distortions of Kerry’s plan. “Although Senator Kerry’s proposals should be subject to a full analysis of their cost and impact, any claim that they amount to ‘government-run health care’ or a ‘government takeover’ of the health care system or of health care decision-making is simply inconsistent with the facts. We are not aware of any expert in health care or health care finance, whatever his or her political orientation, who believes otherwise.”So why would Bush produce an ad like this and continue to raise the specter of “government-run health care” even though the charges are now widely known to be false? Because he keeps getting away with this dishonesty.
Meanwhile the 68 academics that Cohn quotes as opposing the Bush rhetoric represent a middle of the road group of health care economists. The only notable exceptions are Alain Enthoven of Stanford (although his one time colleague Richard Kronick is in the group) and Mark Pauly of Univ. Pennsylvania, the foremost defender of the status quo of the healthcare market. It’s also missing a certain (ex) Stanford Business School professor called Mark McClellan, who’s written extensively about health care and seems to know a thing or two about it. He might want to want to sign this too, but I think his boss might be a little unhappy with him!
Part of the problem is that both sides get their say on the talk shows, with no one (aside from the Columbia Journalism Review or John Stewart) being able to say “this is true — that isn’t”. On a personal note I tend to be able to demolish many arguments I meet with from people complaining about, say, Canadian health care or how inefficient the government program would be, by quoting referred studies that tell the truth. (It’s good to be a researcher wonk when these arguments come up). But there are two problems. One is that a well-financed opposition can cite its own fake studies, and two, no one gives a dam about studies when they have their own fears and anecdotes to back them up.
Hence I’m told again and again that government healthcare would be inefficient (as I heard from a Democrat I met tonight), despite the fact that Medicare’s admin costs are 3% while private insurance’s costs are 8-15%. You’d think that the onus would be on the defenders of the staus quo to show why a change would be worse. But instead–and I realize why–Kerry is running away from any program that could be described as a “government takeover”, even though a rational candidate should be able to defend it. And if I hear Bush say one more time that we have the best healthcare system in the world…..well to say the least he needs to be told by someone that there is a difference between having the most technologically advanced medical spottily applied, and having the best health care insurance and delivery system. There’s a reason we’re ranked number 37 by the WHO, and it’s not just that they’re a bunch of cheese-eating surrender monkeys.
Believe it or not, there’s a very detailed and fair explanation of the Kerry plan by the Heritage Foundation (they of the vast right-wing conspiracy) which goes through it line by line. Heritage of course prefers a consumer-based HSA-type system and (as debated ad nauseam on THCB) as that’s not part of the Kerry agenda they don’t approve. But despite their many criticisms of the Kerry plan, they represent it mostly fairly, unlike their friends on the Republican national committee and at the AEI. They say:
Based on independent estimates, it appears that the Senator’s proposals would significantly increase federal health care spending while substantially reducing the number of Americans who are without insurance coverage. At the same time, he would refrain from undertaking any substantial reform of either private health insurance markets or government health care programs, including Medicaid.
Another detailed commentary on the plan comes from Jeff Lemieux at Centrists.org. Lemiuex’s extremely long examination of the plan suggests that it could be basis for bi-partisan reform to the system, as it relies on a mix of government and private action (or liberal and conservative ideas).
While I’m increasingly convinced that Kerry will win a very close election, I’m inclined to doubt that he’ll get anything like his plan past a Republican house and a very evenly divided Senate. So his plan is a starting point which may–if anything passes and that’s a longshot–work to get more people at the bottom into public programs, allow those in the middle to buy into the FEHBP, and slowly implement DSM programs and other cost saving methods into a more regulated private sector (and hopefully into Medicare too). But it is a long way from being a government dictated-system like that of Canada or the UK. Given the record of American private health care, that may be a bad thing. But the point is government-run health care can’t survive the political rhetoric here. It would be nice if just occasionally Bush would talk something akin to the truth about this issue, but then again why break a 4 year habit?
POLICY/PHARMA: Ross on the flu vaccine
Ross at the The Public Health Press has a just excellent summation of the flu vaccine issue, in the context of the two rather odd replies from Bush and Kerry to that question in last night’s debate.
POLICY: An economist’s forecasts Prop 72’s impact, so it’s incomplete and lacks common sense, with UPDATE
Harvard economist Anna Sinaiko has an article in Health Affiars suggesting that the SB 2 (or Prop 72) “pay or play” law will cause unemployment and reduced wages for those Californians it covers should it pass. Her analysis is manna from heaven to those opposing the bill. Here’s the key conclusion.
Implementing SB 2 will change the behavior of employers affected by the legislation, with consequences for Californias labor market and uninsured citizens…A more likely scenario is that some of the cost of health insurance will be passed to consumers, some felt by workers as unwelcome wage reductions, and some avoided by firms as they restructure their workforces. In California, workers at firms not offering benefits are more likely to be young males earning less than workers at firms that offer insurance; SB 2 will affect this group most adversely.
As a forecaster I was trained to that there’s a big difference between being broadly accurate and precisely wrong. Sinaiko’s detailed analysis of Prop 72’s likely impact falls into the latter category. Increasing labor costs (which is what SB2 will mean) may result in overall lower wages, but increased labor costs are more likely to result in lower profits. Sinaiko never mentions profits as a share of corporate revenues. A senior VP from Fidelity said, in a talk I heard on Monday, that corporate profits as a share of revenues are currently at an all time high, while wages are at their lowest in real terms for 30 years. Why should the costs of SB2 come out of wages rather than profits, given that one of them has been going up and the other down?
Sinaiko correctly points out that the vast majority of jobs affected by SB2 cannot be moved out of California, unless San Franciscans want to drive to Reno to get a cheeseburger. So the total amount of money going into these businesses is likely to stay roughly the same. She almost neglects to mention that the wages of many of those covered by SB2 are at minimum wage or the equivalent (and legally enforced) “living” wage in some cities, so their wages can’t be reduced, and the cost of hiring and managing more part-time employees may exceed the increase in labor costs from SB2.
The broad analysis tells us that, whatever the libertarians say, laws demanding an increase in the lowest levels of compensation (which is in effect what SB 2 is) have almost no impact on unemployment rates, which are driven by the overall economy I lived in the San Francisco Bay Area in 1999 when no amount of money could hire people. I was here in 2002 when you couldn’t get a job no matter how little money you’d work for. (And according to another talk from a different Fidelity executive, all the jobs that could be, had already been moved to India). At both times the minimum wages was the same. In the UK the Labour government brought in a minimum wage in 1999. Today the unemployment rate in the UK is the lowest it’s been since 1972, and studies show no negative impact on employment among low wage workers.
Common sense also suggests that the people who oppose Prop 72 think they have something to lose. Who are those people? They are the big fast food chains and the non-unionized discount stores, who have spent over $8m against it. If they believe that they’ll be able to push all the costs of Prop 72 into their “labor” segment and have none of it come out of their “profit” segment, why would they bother opposing it?
UPDATE: Health Affairs has published a rather more academic version of this letter in its online section.